AQP4 and myeloid sarcoma: The discovery of AQP4-IgG led to the evidence that (1) NMO with positivity for AQP4-IgG is a predominantly an astrocytopathy, and (2) AQP4-IgG is both the pathogenetic cause and the biomarker that defines a distinct disorder which differs from MS.